Skip to main content
Caplight Logo









Marengo Therapeutics

Marengo Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://marengotx.com/

Last Round

Series B

Nov 8, 2021

Total Funding Raised

$119M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Marengo Therapeutics is a biotechnology company that develops precision immunotherapies for cancer and autoimmune diseases through its proprietary T-cell activation platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapysolid tumorsT cell activationbiotechcancer drugcheckpoint inhibitorclinical stage biotechantibody engineeringcombo therapytumor microenvironmentdrug pipelineoncologybiopharmaclinical trial

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Marengo Therapeutics Comparables

Compare Marengo Therapeutics with similar companies based on industry and business-model similarity.

Marengo Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Normunity
84%
Repertoire Immune Medicines
82%
Crossbow Therapeutics
78%

Marengo Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BNov 8, 2021
Series AJan 3, 2018

Key People

Founding team and executive leadership

Svetlana Ni Makhni

Chief Financial Officer

Executive Team

Marengo Therapeutics Investors

Notable investors and investment history

Marengo Therapeutics investors
InvestorRounds
Apple Tree PartnersSeries B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Unveiled partnered STAR program IPN01203/STAR0501, now in Phase 1 trials.

  • Apr 17, 2026

    Initial Phase 2 results for invikafusp alfa in combination with TRODELVY reported at AACR 2026.

Marengo Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Marengo Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Marengo Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range42
Year Founded2015
Last FundingNov 8, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?